Double-Punch immunotherapy trial aims to shrink tumors before surgery
NCT ID NCT07493993
Summary
This study is testing a new combination treatment for people with a type of esophageal cancer that can be surgically removed. Before surgery, patients will receive a two-part immunotherapy drug along with a chemotherapy drug to try to shrink the tumor. The main goal is to see if this approach can completely eliminate the cancer cells in the removed tissue and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.